Nexus Dx was formed in July 2009 to take advantage of current market opportunities in Point of Care diagnostics and is dedicated to improving patient outcomes and healthcare economics via decentralized blood diagnostics. Nexus Dx will define, develop and commercialize diagnostic products based on its immunochemistry and nucleic acid platforms.
Nexus Dx was acquired from ITC Nexus Holding Company, by Samsung Electronics' Health and Medical Equipment Division (HME). Ed Brennan joined the new entity as CEO.
Nexus Dx merged with International Technidyne Corporation, a company specializing in the monitoring of anti-coagulation therapies, to form ITC Nexus Holding Company.
Nexus Dx acquired the Point of Care assets of Nanogen, Inc.